HBM Healthcare Investments AG

Equities

HBMN

CH0012627250

Investment Management & Fund Operators

Market Closed - Swiss Exchange Other stock markets 11:30:56 2024-09-12 am EDT			5-day change	1st Jan Change
168.60 ^CHF	-1.40%		-4.20%	-7.67%

Jul. 25	Chemomab Therapeutics to Raise $10 Million From Private Placement; Shares Fall	MT
Jul. 19	HBM Healthcare Investments AG Reports Earnings Results for the First Quarter Ended June 30, 2024	CI

HBM Healthcare Investments : IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%)

March 22, 2021 at 01:49 am EDT

EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%)

22-March-2021 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

With Instil Bio (Nasdaq: TIL) and Connect Biopharma (Nasdaq: CNTB), two more private companies from the HBM Healthcare Investments portfolio successfully went public last Friday.

Instil Bio raised USD 320 million in new capital by issuing 16 million shares at a price of USD 20.00 per share. On the first day of trading, the share price rose to USD 26.44 (+32.2%).

HBM Healthcare Investments has invested a total of USD 12.5 million in Instil Bio since June 2020. The investment was previously valued at USD 20.3 million based on the last financing round. A further USD 6 million was invested in the IPO. Following the IPO, HBM Healthcare Investments thus holds 2.2 million shares with a total value of USD 59.1 million.

Instil Bio is developing a cell therapy pipeline with autologous tumour-infiltrating lymphocytes (TIL) for the treatment of cancer. The lead TIL candidate, ITIL-168, is being developed for the treatment of advanced melanoma.

Connect Biopharma raised USD 191.3 million through the IPO by issuing 11.25 million American Depositary Shares (ADS) at a price of USD 17.00 per ADS. The shares closed at USD 18.49 (+8.8%) on the first day of trading.

HBM Healthcare Investments invested USD 10 million in Connect Biopharma in August 2020 and increased its stake by a further USD 5.1 million at the IPO. Following the IPO, HBM Healthcare Investments holds 1.2 million ADS worth USD 22.4 million.

Connect Biopharma develops therapies for the treatment of T-cell related inflammatory diseases. The company has a pipeline of four drug candidates. The two most advanced clinical-stage programmes, CBP-201 and CBP-307, are potentially differentiated product candidates against validated targets for the treatment of atopic dermatitis and ulcerative colitis and Crohn's disease.

End of ad hoc announcement

Language:	English
Company:	HBM Healthcare Investments AG
	Bundesplatz 1
	6300 Zug
	Switzerland
Phone:	+41438887171
Fax:	+41438887172
E-mail:	info@hbmhealthcare.com
Internet:	https://www.hbmhealthcare.com
ISIN:	CH0012627250
Valor:	1262725
Listed:	SIX Swiss Exchange
EQS News ID:	1177130


End of Announcement	EQS Group News Service

1177130 22-March-2021 CET/CEST

Latest news about HBM Healthcare Investments AG

Chemomab Therapeutics to Raise $10 Million From Private Placement; Shares Fall	Jul. 25	MT
HBM Healthcare Investments AG Reports Earnings Results for the First Quarter Ended June 30, 2024	Jul. 19	CI
HBM Healthcare Investments Swings to Profit in Q1	Jul. 19	MT
Cartesian Therapeutics Secures $130 Million Private Placement Equity Financing	Jul. 02	MT
HBM Healthcare Flags NAV Boost from Yellow Jersey-Johnson & Johnson Deal	May. 28	MT
HBM Healthcare Investments' Portfolio Company to Buy Laboratorios Biopas Group	May. 23	MT
HBM Healthcare Investments' Net Loss Narrows in FY24	May. 09	MT
HBM Healthcare Investments AG Reports Earnings Results for the Full Year Ended March 31, 2024	May. 08	CI
Tranche Update on HBM Healthcare Investments AG's Equity Buyback Plan announced on July 5, 2023.	May. 08	CI
HBM Healthcare Investments Warns of CHF1 Million Loss for FY24	Apr. 03	MT
Tranche Update on HBM Healthcare Investments AG's Equity Buyback Plan announced on July 5, 2023.	Jan. 30	CI
HBM Healthcare Investments AG Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 22	CI
HBM Healthcare Investments Logs Lower Fiscal Q3 Loss	Jan. 22	MT
HBM Healthcare Investments Warns of FY24 Nine-month Net Loss	Jan. 04	MT
AbbVie to Buy Cancer-focused ImmunoGen for $10.1 Billion	Nov. 30	MT
Kepler Cheuvreux Lowers Price Target on HBM Healthcare Investments, Maintains Buy Recommendation	Nov. 21	MT
HBM Healthcare Investments Launches Share Buyback	23-10-16	MT
HBM Healthcare Investments AG Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-16	CI
HBM Healthcare Investments Logs Higher Fiscal H1 Loss	23-10-16	MT
Tranche Update on HBM Healthcare Investments AG's Equity Buyback Plan announced on July 5, 2023.	23-10-16	CI
HBM Healthcare Investments Flags Fiscal H1 Loss	23-10-03	MT
HBM Healthcare Investments AG Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-21	CI
HBM Healthcare Investments' Ficsal Q1 NAV Per Share Declines	23-07-21	MT
HBM Healthcare Investments AG commences an Equity Buyback Plan under the authorization approved on June 10, 2022.	23-07-05	CI
HBM Healthcare's Portfolio Company Cathay Biotech to Sell Shares for CNY6.6 Billion	23-06-26	MT

Chart HBM Healthcare Investments AG

Duration

Period

More charts

Company Profile

HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.

Employees

700

Sector

Investment Management & Fund Operators

Calendar

2024-10-20 - Q2 2025 Earnings Release

More about the company